Skip to content
Companies

Episteme Prognostics

Test predicting chemo response in pancreatic cancer

Raised to date

$550K

of $2.5M offered across 1 Form D filing

Still open
$1.9M
Investors
1
Last filed
Mar 10, 2025

About

Episteme Prognostics, Inc. is a pioneering precision medicine company dedicated to revolutionizing pancreatic cancer diagnosis and treatment. By focusing on the development of groundbreaking diagnostic tests, the company aims to enhance therapeutic decisions, ultimately improving patient outcomes. Their innovative technology leverages epigenetic biomarkers to provide critical insights into treatment responses for patients diagnosed with this challenging disease.

Episteme Prognostics stands out by utilizing epigenetic biomarkers to create diagnostic tools that predict therapeutic responses in pancreatic cancer, an area with historically limited options.

Funding

  • Option to acquireFiled Mar 10, 2025Form D
    $550K/ $2.5M

Product

PancEpistemeDx

Diagnostic testing

PancEpistemeDx is a proprietary rapid diagnostic test designed specifically for pancreatic cancer patients. This innovative test evaluates tumor samples to predict how patients will respond to first-line chemotherapy treatments. By identifying responders, this test plays a crucial role in personalizing cancer care.

  • Rapid diagnostic results
  • Uses epigenetic biomarkers
  • Predicts chemotherapy response

Built for

Oncologists and healthcare providers

People on file